Levothyroxine Supplementation for Heart Transplant Recipients

Recruiting now · Phase 1 · Has a placebo group

Conditions studied: Heart Transplant Failure, Heart Transplant Infection

In brief

This will be a prospective, randomized study performed at a single tertiary referral academic medical center (University of California San Francisco, CA), evaluating the survival benefits of levothyroxine compared with no levothyroxine for patients who have undergone heart transplant. It will be double-blinded and placebo-control; participants will be randomized to receive levothyroxine or receive no levothyroxine.

Key facts

Study ID

NCT06428097

Run by

University of California, San Francisco

People needed

97

Starts

2024-03-29

Expected to finish

2027-03-01

Last updated by the study team

2025-05-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants must be listed for heart transplantation
• Age ≥18 years
• Ability to understand and the willingness to sign a written informed consent document.

You may not qualify if…

• Patients with pre-existing thyroid related condition including hypothyroidism, hyperthyroidism and malignancy
• Patients with a known allergy or intolerance to levothyroxine
• Patients participating in another study evaluating an investigational drug within the past 30 days.

Where it is running

• University of California, San Francisco — San Francisco, California, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.